Globus Medical (GMED)
Builds spine and orthopedic systems spanning implants, robotics, navigation, and pain therapies.
Something off on this page? Send us feedback.
Develops spine and orthopedic implants, robotic navigation, imaging, surgical planning, neuromonitoring, and chronic-pain therapies. Operates globally through Musculoskeletal Solutions and Enabling Technologies within one reportable segment, with growth shaped by repeated product launches and acquired portfolios.
Develops musculoskeletal products and enabling technologies for spine, orthopedic trauma, joint reconstruction, biologics, and chronic pain. The Excelsius ecosystem combines surgical planning, imaging, navigation, and robotics, while intraoperative neuromonitoring adds a service component.
Operates globally as one reportable segment, selling through direct representatives and distributors. An engineering-led model centered on surgeon feedback, repeated product launches, and selective acquisitions has broadened a spine-focused franchise through the NuVasive and Nevro combinations.
Execution depends on surgeon and hospital adoption, regulatory clearances, quality-system compliance, acquired-business integration, intellectual-property protection, and reliable direct and distributor channels. Whether the FDA warning letter concerning ExcelsiusGPS quality systems and medical-device reporting has been closed is not publicly confirmed.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $82 |
| Jul 16, 2026 | Truist Financial | Target | Target: $115 | Target: $100 |
| Jul 13, 2026 | RBC Capital | Reiterate | Rating: —Target: $100 | Target: $115 |
| Jul 8, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $94 |
| Jul 8, 2026 | Stifel Nicolaus | Target | Target: $64 | Target: $80 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $595.1M · Total debt $111.2M · Total assets $5.49B · Shareholders' equity $4.77B
- Revenue
- $789.6M
- Operating income
- $182.4M
- Net income
- $151.6M
No dividends on record.
| Institutions | 89.54% | 120.21M shares | |
|---|---|---|---|
| 615 holders · as of Jun 30, 2026 | |||
| Insiders | 22.28% | 29.92M shares | |
| 5 holders · as of Jul 28, 2026 | |||
| Strategic holders | 5.24% | 7.03M shares | |
| 1 holder · as of May 14, 2025 | |||
| Adds to | 117.06% | ||
134.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 117.06%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David C. Paul1Insiderdirector, 10 percent owner, officer: Executive Chairman | 16.88% | 22.43M · 171,100 | filed Dec 10, 2025 |
BlackRock, Inc.Institution | 8.05% | 10.81M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 6.11% | 8.20M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 5.24% | 7.03M | filed May 14, 2025 |
Ein #.Insider | 4.86% | 6.53M | filed Feb 10, 2022 |
- David C. Paul's transaction reports restate only vehicles that traded; the 2022 ownership statement (22.43M) plus the 60.4K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | James R. Tobin | director | −30,000 | $74.58 |
| Aug 18, 2026 | Stephen T. Zarrilli | director | −25,000 | $87.04 |
| Jun 5, 2026 | David D. Davidar | director | −25,000 | $80.76 |
| Feb 25, 2026 | Kelly Huller | officer: EVP, GC, Corporate Secretary | −20,000 | $94.50 |
| Feb 12, 2026 | Kelly Huller | officer: EVP, GC, Corporate Secretary | −10,000 | $87.67 |
- Medtronic
Spine, surgical-enablement, and pain-stimulation rival
- Johnson & Johnson
Orthopaedics rival across spine, robotics, trauma, and joints
- Stryker
Spine robotics, joint reconstruction, and trauma overlap
- Alphatec
Spine-focused rival in implants, imaging, monitoring, and navigation
- Zimmer Biomet
Joint-reconstruction, robotics, and trauma/extremities competitor
- Smith & Nephew (ADR)
Hip/knee reconstruction, robotics, and trauma overlap
- Orthofix Medical
Spine, biologics, navigation, and limb-reconstruction rival
- Boston Scientific
Spinal-cord-stimulation rival in chronic pain neuromodulation
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Globus Medical | $74.81 | −0.51% | $10.14B | 19.3 | 14.6 | 3.2 | +5.9% |
| Medtronic | $90.57 | −0.22% | $116.19B | 22.4 | 15.1 | 3.1 | +13.7% |
| Johnson & Johnson | $269.90 | +0.26% | $648.72B | 31.2 | 22.7 | 6.6 | +6.6% |
| Stryker | $273.71 | −0.49% | $105.45B | 28.5 | 17.1 | 4.1 | +9.4% |
| Alphatec | $10.14 | −1.88% | $1.59B | — | 20.1 | 1.9 | +15.1% |
| Zimmer Biomet | $90.74 | −3.44% | $18.18B | 22.9 | 10.4 | 2.1 | +4.8% |
| Smith & Nephew (ADR) | $26.94 | −2.04% | $11.55B | 18.8 | — | 1.8 | +4.6% |
| Orthofix Medical | $9.06 | +0.89% | $363.0M | — | — | 0.4 | +5.1% |
| Boston Scientific | $44.98 | +0.12% | $66.77B | 18.3 | 13.7 | 3.2 | +7.5% |
| Median | 22.6 | 16.1 | 2.6 | +7.1% |